Company: EDSA
Filing Date: 2025-12-12
Form Type: 10-K
Source: 0001171843-25-007914
Chunk: 233

Company: Edesa Biotech, Inc.
Filing Date: 2025-12-12
Form: 10-K
Item: Item 1
Chunk 233
---
Proceeds from issuance of Series A-1 preferred shares and warrants

			1,540,820

			-

			Proceeds from issuance of Series B-1 preferred shares

			8,340,000

			-

			Payments for issuance costs of common shares and warrants

			(328,953
			)

			(107,824
			)

			Payment for issuance costs of preferred shares

			(215,157
			)

			-

			Payment for issuance costs of warrants

			(23,446
			)

			-

			Repayment of debt

			-

			(29,532
			)

			Net cash provided by financing activities

			17,030,898

			592,031

			Effect of exchange rate changes on cash and cash equivalents

			46,216

			(25,903
			)

			Net change in cash and cash equivalents

			9,754,852

			(4,324,077
			)

			Cash and cash equivalents, beginning of year

			1,037,320

			5,361,397

			Cash and cash equivalents, end of year

			$
			10,792,172

			$
			1,037,320

The accompanying notes are an integral part of these consolidated financial statements.

F-6

EDESA BIOTECH, INC.

Consolidated Statements of Changes in Shareholders’ Equity

			Shares #

			Common Shares

			Series A-1 Preferred Shares 

			Series B-1 Preferred Shares 

			Additional Paid-in Capital

			Accumulated Other Comprehensive Loss

			Accumulated Deficit

			Total Shareholders' Equity

			Balance - September 30, 2023

			3,075,473

			$
			46,643,151

			$
			-

			$
			-

			$
			13,039,265

			$
			(214,648
			)
			 
			$
			(52,418,968
			)
			 
			$
			7,048,800

			Issuance of common shares upon exercise of warrants

			171,916

			729,387

			-